Researchers have shown that a prostate cancer urine test can identify men at ‘intermediate risk’ who can safely avoid immediate treatment and benefit from ‘active surveillance’ instead. Previously, the team’s Prostate Urine Risk (PUR) test could identify men with high and low risk cancers. But thanks to some fine-tuning, it can now help men with intermediate-risk disease – for whom treatment options had been less clear.